ACOG Financials: Alpha Cognition Inc AI Analysis

Home

Stock

ACOG

Financials

ACOG Financial

Alpha Cognition Inc

$5.32

-4.83%

$-0.26

At close: Mar 25, 16:00:00 GMT-4

$5.22

-1.87%

$-0.1

Post-market: Mar 25, 19:35:15 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$5.59

Open

$5.59

Day's Range

$5.22 - $5.59

52 week range

$3.75 - $11.54

Volume

34.9K

Avg.Volume

74.5K

Dividend yield

EPS (TTM)

-1.37

Market Cap

$113.4M

What is ACOG?

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

ACOG Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022
Revenue	7	0	0	0
Revenue Growth (YoY)	--	--	--	--
Cost of Revenue	1	--	--	--
Gross Profit	5	--	--	--
Selling, General & Admin	20	7	4	4
Research & Development	2	3	4	9
Operating Expenses	22	11	9	13
Other Non Operating Income (Expenses)	0	0	0	--
Pretax Income	-19	-14	-13	-12
Income Tax Expense	--	--	--	--
Net Income	-19	-14	-13	-12
Net Income Growth	--	8%	8%	--
Shares Outstanding (Diluted)	16.14	7.24	3.58	2.71
Shares Change (YoY)	--	102%	32%	--
EPS (Diluted)	-1.2	-2.01	-3.83	-4.45
EPS Growth	--	-47%	-14%	--
Free Cash Flow	-15	-7	-8	-9
Free Cash Flow Per Share	--	--	--	--
Gross Margin	71.42%	--	--	--
Operating Margin	-242.85%	0%	0%	0%
Profit Margin	-271.42%	0%	0%	0%
Free Cash Flow Margin	-214.28%	0%	0%	0%
EBITDA	-17	-11	-9	-13
EBITDA Margin	-242.85%	0%	0%	0%
D&A For EBITDA	0	0	0	0
EBIT	-17	-11	-9	-13
EBIT Margin	-242.85%	0%	0%	0%
Effective Tax Rate	--	--	--	--

Follow-Up Questions

What are Alpha Cognition Inc's key financial statements?



According to the latest financial statement (Form-10K), Alpha Cognition Inc has a total asset of $50, Net loss of $-14

What are the key financial ratios for ACOG?



Alpha Cognition Inc's Current ratio is 5.55, has a Net margin is 0, sales per share of $0.

How is Alpha Cognition Inc's revenue broken down by segment or geography?



Alpha Cognition Inc largest revenue segment is Antibody-based Therapies, at a revenue of 74,205,000 in the most earnings release.For geography, United States is the primary market for Alpha Cognition Inc, at a revenue of 74,205,000.

Is Alpha Cognition Inc profitable?



no, according to the latest financial statements, Alpha Cognition Inc has a net loss of $-14

Does Alpha Cognition Inc have any liabilities?



yes, Alpha Cognition Inc has liability of 9

How many outstanding shares for Alpha Cognition Inc?



Alpha Cognition Inc has a total outstanding shares of 16.01

Alpha Cognition Inc (ACOG) Financial

ACOG Stock Price Chart